Logo Logo
Switch Language to German

Gerl, Arthur (2000): Cisplatin-based chemotherapy of testicular cancer - Two decades after a major breakthrough. In: Onkologie, No. 2: pp. 106-111 [PDF, 70kB]

[thumbnail of 10_1159_000027081.pdf]
Download (70kB)


Two decades ago the introduction of cisplatin-based combination chemotherapy has dramatically improved the prognosis of patients with metastatic testicular cancer, At present 3 cycles of cisplatin, etoposide and bleomycin are considered as standard treatment for good-risk metastatic disease. Outside of clinical trials patients in the intermediate and poor prognosis categories should receive 4 cycles of this standard regimen, Clinical trials currently evaluate the role of high-dose chemotherapy in first-line treatment of high-risk patients and in the salvage setting, Post-chemotherapy resection of tumor residuals remains an important part of therapy. Attention should be focused on long-term toxicity of therapy and the occurrence of late relapse.

Actions (login required)

View Item View Item